MedTrace Logo

Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis

NCT02542787 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2018-03-02

No results posted yet for this study

Summary

Phase II a Proof of concept study in Multiple Sclerosis (MS) patients with spasticity.

Conditions

  • Spasticity in People With Multiple Sclerosis

Interventions

DRUG

VSN16R

Small molecule

OTHER

Placebo

dummy tablet

Sponsors & Collaborators

  • Canbex Therapeutics Ltd

    lead INDUSTRY

Principal Investigators

  • Dr Rachel Farrell · University College London Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02542787 on ClinicalTrials.gov